Company Research Report: Invetx
Company Overview
Name: Invetx
Mission of the Company: To drastically elevate the standard of care for animal diseases and chronic conditions such as pain, allergy, cancer, and diabetes using biopharmaceuticals, providing highly targeted, effective, and safe therapies while easing pet owners from the burden of daily administration.
Founded: No information is available
Founders: No information is available
Key People in the Company:
- Jürgen Horn, Chief Executive Officer
- Colin Giles, Chief Development Officer
- William Brondyk, Chief Scientific Officer
- Jeff Troderman, Chief Financial Officer and Inside Counsel
- Krishnan Sampath, Chief Technology Officer
- Dusty Brown, Associate Director, CMC Operations
- Robert Zolynas, Vice President, Clinical and Regulatory Affairs
- Leila Sevigny, Senior Director of Drug Discovery
- Joachim Hasenmaier, Board of Directors
- Marcus Remmers, Board of Directors
Headquarters: Boston, Massachusetts
Number of Employees: No information is available
Revenue: No information is available
What the Company is Known For: Invetx is known for pioneering protein-based therapeutics for animal health with a particular focus on creating novel veterinary biotherapeutics. They specialize in developing monoclonal antibodies (mAbs) for chronic and serious conditions in dogs and cats.
Products
Products Offering:
- Monoclonal Antibodies (mAbs): Engineered proteins targeting specific receptors or ligands linked to diseases or conditions.
High-Level Description of the Products:
- IVX-01: A proprietary, novel, fully canine, high-affinity, and half-life extended monoclonal antibody for chronic conditions in dogs.
Key Features of the Products:
- Accuracy in targeting specific disease-related receptors
- Extended duration of activity
- Fewer side effects due to targeted action
- Significantly improved half-life, increasing the interval between doses
Recent Developments
Partnerships and Collaborations:
- Twist Bioscience: Expanded partnership for the discovery of best-in-class antibodies to treat multiple diseases in cats and dogs.
- Boehringer Ingelheim: Strategic collaboration to advance monoclonal antibody biotherapeutics in animal health.
- AbCellera: Expanded multi-year antibody discovery collaboration focused on animal health.
New Product Launches:
- IVX-01: Initiated first clinical study in dogs targeting a chronic condition.
Technological Developments:
- Half-Life Extension Platform: Completed development of a species-specific half-life extension technology that significantly enhances the duration of monoclonal antibody treatments in dogs and cats.
- Canine and Feline Technology Platform: Developed to optimize antibody drug treatment options for chronic, serious diseases in dogs and cats.
Recent Financing:
- Series B Financing: Raised $60.5 million to advance the portfolio of best-in-class veterinary biotherapeutics.
- Total Raised: $86 million since 2018.
Acquisition:
- Dechra Pharmaceuticals: Announced upcoming acquisition by Dechra Pharmaceuticals for up to $520 million.
Market Insights:
- A market research study by Invetx revealed nearly 40% of dogs in the U.S. suffer from chronic osteoarthritis/pain, with veterinarians and pet owners preferring longer-acting therapeutics.
Board Appointments:
- Marcus Remmers: Appointed to Invetx’s board of directors.
No additional commentary is provided at the end of this detailed market research report.
